Life sciences: Industry Pulse

Could longevity become the next major market in life sciences? Once confined to academic imagination, advances in geroscience are bringing that possibility closer to reality. This report examines the field’s progress, from clinical-stage therapies targeting aging mechanisms and growing interest in GLP-1s as “anti-aging” drugs to AI-driven drug discovery. It also explores the role of aging biomarkers and the regulatory hurdles and commercial realities that could shape the future of this potentially transformative field.

In this report, we explore the state of longevity and the factors shaping its future, including:

• How advances in geroscience are moving therapies targeting aging-related mechanisms into drug development
• The regulatory hurdles and investment trends that could shape the commercial case
• How GLP-1s are redefining the conversation around anti-aging therapeutics
• Why the brain may be one of the toughest challenges in extending healthspan